Abualbishr Alshreef BPharm, MPH, MSc
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 0673
Fax: (+44) (0)114 222 0749
I am a Research Fellow in Health Economics and Decision Modelling and NIHR Doctoral Research Fellow based in the School of Health and Related Research (ScHARR). The aim of my PhD research project is to develop a methodological framework to account for the impact of non-adherence on the cost-effectiveness of prescribed chronic medications.
I joined ScHARR (HEDS) as a Research Associate in Health Economics and Decision Modelling in
December 2014 after completing an MSc in Health Economics at the University of York. I undertook a
summer placement at the Centre for Health Economics (CHE) at University of York in 2014. My
research project at CHE was focused on methods to account for follow-up time differences when
calculating QALYs from randomised controlled trials.
Since joining ScHARR I have worked on a range of research and consultancy projects. My work has
been focused on economic evaluation and related methodological research. I have completed several
projects including: economic evaluations alongside clinical trials, cost-effectiveness modelling studies,
a review of economic submissions to the NICE Medical Technologies Evaluation Programme and a
methodological project on developing decision-making frameworks for NICE Technology Appraisal
Prior to this, I worked for the health insurance and pharmaceutical industries. My work was mainly
focused on applied research, market access and pharmaceuticals reimbursement decisions.
My research interests include economic evaluations alongside clinical trials, decision-analytic
modelling for cost-effectiveness analysis, and early-stage economic evaluation of medical devices
and other innovations.
During my previous research experience, I worked on many disease areas including depression,
dementia, diabetes, stroke, haemorrhoids, breast cancer, ophthalmology and urinary incontinence.
My teaching interests are economic evaluation and quantitative research methods. My current
teaching activities involve:
- Economic Evaluation and Health Care Financing (HAR687) in the
Master of Public Health (MPH) programmes.
- Associate Fellow of the Hight Education Academy (AFHEA).
- Co-lead on Internationalisation in HEDS and member of ScHARR’s Internationalisation Committee.
- Member of the UK Health Economists’ Study Group (HESG).
- Member of International Society for Pharmacoeconomics and Outcome Research (ISPOR).
- NIHR Doctoral Research Fellowship
- Davies MJ, Kristunas CA, Alshreef A, Dixon S, Eborall H, Glab A, Huddlestone L, Hudson N, Khunti K, Martin G , Northern A et al (2019) The impact of an intervention to increase uptake to structured self-management education for people with type 2 diabetes mellitus in primary care (the embedding package), compared to usual care, on glycaemic control : study protocol for a mixed methods study incorporating a wait-list cluster randomised controlled trial. BMC Family Practice, 20. View this article in WRRO
- Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J & Dixon S (2019) Statistical methods for adjusting estimates of treatment effectiveness for patient nonadherence in the context of time-to-event outcomes and health technology assessment: A systematic review of methodological papers. Medical Decision Making. View this article in WRRO
- Palmer R, Dimairo M, Cooper C, Enderby P, Brady M, Bowen A, Latimer N, Julious S, Cross E, Alshreef A , Harrison M et al (2019) Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS) : a multicentre, single-blinded, randomised controlled trial. The Lancet Neurology, 18(9), 821-833. View this article in WRRO
- Alshreef A, MacQuilkan K, Dawkins B, Riddin J, Ward S, Meads D, Taylor M, Dixon S, Culyer AJ, Ruiz F , Chalkidou K et al (2019) Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. Value in Health Regional Issues, 19, 65-74. View this article in WRRO
- Jha S, Walters SJ, Bortolami O, Dixon S & Alshreef A (2017) I mpact of P elvic Floor Muscle Training on S exual function of women with U rinary Incontinence and a comparison of electrical stimulation versus standard treatment (IPSU Trial): a randomised controlled trial. Physiotherapy. View this article in WRRO
- Alshreef A, Wailoo AJ, Brown SR, Tiernan JP, Watson AJM, Biggs CE, Bradburn M & Hind D (2017) Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial. PharmacoEconomics Open. View this article in WRRO
- Brown S, Tiernan J, Biggs K, Hind D, Shephard N, Bradburn M, Wailoo A, Alshreef A, Swaby L, Watson A , Radley S et al (2016) The HubBle trial: Haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: A multicentre randomized controlled trial and health-economic evaluation. Health Technology Assessment, 20(88), 1-180. View this article in WRRO
- Alshreef A, Jenks M, Green W & Dixon S (2016) Review of Economic Submissions to NICE Medical Technologies Evaluation Programme. Applied Health Economics and Health Policy, 14(6), 623-634. View this article in WRRO
- Brown SR, Tiernan JP, Watson AJM, Biggs K, Shephard N, Wailoo AJ, Bradburn M, Alshreef A & Hind D (2016) Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial. The Lancet, 388(10042), 356-364. View this article in WRRO
- Alshreef A () Provider Payment Mechanisms: Effective Policy Tools for Achieving Universal and Sustainable Healthcare Coverage, Universal Health Coverage [Working Title] IntechOpen View this article in WRRO
Conference proceedings papers
- Pennington B, Alshreef A, Flight L, Hykin P, Sivaprasad S, Brazier JE & Hernández M (2019) PSS25 MAPPING FROM VISUAL ACUITY TO UTILITY IN PATIENTS WITH MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION USING DATA FROM THE LEAVO TRIAL. Value in Health, Vol. 22 (pp S891-S891)
- Flight L, Alshreef A, Hykin PG, Sivaprasad S, Pennington B, Kelly J, Murphy CL & Brazier JE (2019) PIN156 INTRAVITREAL THERAPY WITH RANIBIZUMAB VS AFLIBERCEPT VS BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION: A WITHIN TRIAL COST-UTILITY ANALYSIS. Value in Health, Vol. 22 (pp S664-S664)
- Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018.
- Alshreef A, Macquilkan K, Dawkins B, Riddin J, Ward S, Meads D, Taylor M, Dixon S, Culyer T, Hofman K , Ruiz F et al (2018) Assessing the Appropriateness of Existing Model Adaptation Methods for Low and Middle-Income Countries. Value in Health, Vol. 21 (pp S8-S8)
- Alshreef A & Wailoo A (2017) Haemorrhoidal Artery Ligation Procedure For The Treatment of Symptomatic Grade II–III Heamorrhoids: A Trial-Based And Long-Term Model-Based Economic Evaluation. Value in Health, Vol. 20(9) (pp A666-A666)
- Goodall M, Tosh J, Alshreef A & Tappenden P (2016) Conceptual Modelling for Cost-Effectiveness Analysis of Intravitreal Therapy with Ranibizumab, Aflibercept or Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion. Value in Health, Vol. 19(7) (pp A366-A366) View this article in WRRO
- Alshreef A & Spackman E (2015) Methods to Account for Follow-Up Time Differences when Calculating Qalys from Randomised Controlled Trials. Value in Health, Vol. 18(7) (pp A711-A711)